Active — Not RecruitingPhase 1

A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

United States30 participantsStarted 2026-03-23

Plain-language summary

The goal of this study is to learn what happens to enlicitide (MK-0616) in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of enlicitide and if people tolerate it.

Who can participate

Age range19 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health * Has a body-mass index (BMI) between 18 and 32 kg/m\^2 Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of clinically significant gastrointestinal disease that may impact drug absorption * Has a history of cancer (malignancy)

What they're measuring

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of enlicitide

Timeframe: At designated timepoints up to approximately 50 days

Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of enlicitide

Timeframe: At designated timepoints up to approximately 50 days

Maximum Plasma Concentration (Cmax) of enlicitide

Timeframe: At designated timepoints up to approximately 50 days

Trial details

NCT IDNCT07481708

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05-18

View on ClinicalTrials.gov More Healthy trials